GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Does Cell Dose Affect Treatment Cost?

Yes, cell dose can affect treatment cost, but the price does not necessarily rise in proportion to the cell count. A higher dose may cost more if the provider charges for additional cell preparation, batches or administrations. A bundled course may cover a range of doses without a price increase. To compare offers, check the cells per administration, the number of administrations and the full-course price—not the headline cell count alone.

For example, 100 million cells given twice means 200 million cells over the course. It is not the same offer as 100 million cells given once, even if both quotes advertise “100 million cells.” These numbers illustrate the arithmetic, not a recommended dose or an actual clinic quotation.

Does Cell Dose Affect Treatment Cost?

What the Dose Number Means

Record the cell type, tissue source, route of administration and whether the cells come from you or a donor. Then ask whether the stated count is per injection, per joint, per visit or for the entire course. Also ask whether it refers to total cells or viable cells intended for administration, and whether the count is measured before freezing or after thawing.

Some treatments use a weight-based dose. A retrospective Norwegian study of 189 patients with blood cancers examined CD34-positive cells per kilogram in peripheral blood stem cell grafts from matched sibling donors. It studied transplant outcomes, not prices or private-clinic mesenchymal stromal cell injections PMC8432346. Do not use a transplant dose target as a benchmark for an unrelated MSC treatment quote.

When More Cells Change the Price

Ask the provider what changes between the lower-dose and higher-dose options. Does the higher dose require another production batch, additional processing, a different collection procedure or another administration? Which of those changes appears as an extra charge? The steps described in the treatment process in Japan can help you identify the items to ask about, but your written quotation determines what is included.

More cells do not automatically mean more culture days, more safety tests or twice the laboratory work. If two dose options fall within the same fixed-price package, the quoted fee may be identical. If the provider charges by cell quantity, request the unit rate, minimum charge and total course price. Do not assume that every clinic uses the same pricing model.

The patient’s own cells are called autologous cells; cells from another person are allogeneic, or donor, cells. Donor sourcing avoids collecting those cells from the recipient, but it does not make processing, screening or administration free. When comparing autologous and allogeneic options, ask for the complete costs of each plan rather than assuming one source is cheaper.

Check the Pricing Unit

Questions to ask about each possible pricing basis
Pricing basis What to confirm How dose can affect the total
Per cell quantity The rate, counting method and minimum charge A larger billable quantity may increase the cell charge; other fees still need checking.
Per administration The included dose and fee for each infusion or injection More administrations can add charges even if the dose per administration stays the same.
Per joint or site Whether the stated dose and price apply to one site or all treated sites Two sites may be billed separately rather than as one larger dose.
Per course The included dose range, session count and follow-up period A dose change may be included, while an extra session may not be.
Storage or later use Storage period, transport, thawing and any testing or administration charges Banked cells do not necessarily include the cost of using them later.

Compare Two Quotes on the Same Basis

Hypothetical comparison: Plan A provides 100 million cells in one administration. Plan B provides 100 million cells at each of two administrations, four weeks apart. Their course totals are 100 million and 200 million cells respectively. The interval is part of this illustration, not treatment advice.

Before deciding which offer costs less, write down the full-course yen total for each plan, including applicable tax and all mandatory charges. Ask whether each administration includes its own consultation, tests and follow-up, or whether those items are bundled. Do not assume that two visits mean twice every fee.

Ask: “Does this price cover the entire planned course, or only one administration? Please list the total cell count, session count, included services and any charges payable later.”

If a provider quotes a price per million cells, compare that rate only after confirming the same cell type, counting basis and included services. A lower unit price does not establish better medical value. Keep the full-course total visible alongside the rate. The site’s Japan treatment-cost information is a navigation resource; obtain a current, individualized quotation from the treating provider.

Does a Higher Dose Offer Better Value?

A higher cell count is not, by itself, evidence of greater benefit. Ask for human evidence comparing doses for your diagnosis, cell product and route. Check the study design, comparison group, sample size, outcome measured, follow-up period and adverse events. A trial testing one regimen cannot establish that doubling its dose improves the result.

For a defined example, the FDA approved Ryoncil, a donor bone marrow-derived MSC therapy, on 18 December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. This is a serious complication of donor blood stem cell transplantation. The supporting multicenter, single-arm study enrolled 54 children. Its initial regimen was eight intravenous infusions over four weeks; participants with partial or mixed responses received additional weekly infusions for four weeks. At day 28, 30% had a complete response and 41% had a partial response Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.

Those results concern one product, disease and pediatric population, with no randomized comparison group. They do not show that a higher private-clinic dose is worth a higher price for knee symptoms, diabetes or anti-aging. The FDA announcement provides treatment and outcome information, not a price estimate. It also shows why an initial regimen should not automatically be treated as the maximum number of administrations.

A study registration is not proof that a treatment works. The FDA also warns that inclusion in ClinicalTrials.gov or registration of a firm with FDA does not establish that a product is legally marketed Important patient and consumer information about regenerative medicine therapies. Ask for the actual human results and the treatment’s regulatory status, not just a registry number.

Check the Treatment’s Status in Japan

For care covered by Japan’s Act on the Safety of Regenerative Medicine, the hospital or clinic must obtain the relevant certified committee’s opinion and submit a provision plan to the Ministry of Health, Labour and Welfare. Requirements depend on the treatment’s risk category. Submission of that plan is not the same as marketing approval of a regenerative medical product En.

PMDA describes the separate frameworks for clinical provision under that Act and commercialization of regenerative medical products under the PMD Act, and links to approved-product information 0003. Ask whether the quote concerns an approved product used within its approved indication, a research intervention or a private-pay service under a provision plan. A plan number alone does not prove that the proposed dose is effective for your condition. The site’s registration and compliance overview provides related navigation, not independent proof of efficacy.

Get the Full Cost in Writing

Use the same checklist for each provider. Mark an item as included, excluded or not applicable; do not leave it blank.

  • Dose: cell type and source, route, count per administration, number of administrations, intervals and course total.
  • Preparation: consultation, collection, anesthesia if applicable, culture or processing, quality checks and release criteria. Ask which work is done at the cell processing center and which charges are included.
  • Delivery: transport, storage, thawing, administration, imaging if needed and observation.
  • Aftercare: scheduled tests, outcome checks, follow-up duration and the fees for additional visits.
  • Failure or change: what you owe if collection is inadequate, culture or release fails, fewer cells are available, or treatment is postponed or cancelled.
  • Payment: the yen total, applicable tax, deposit, quotation validity and refund terms.
  • Travel: interpreter, flights, lodging and possible return visits. Use the medical travel guide to plan these separately from the medical fee.

If two options differ in dose, ask the clinician to explain the medical reason for the difference before comparing price. Also ask about established care, no intervention where appropriate and eligible clinical trials. A lower-dose commercial package is not automatically the best alternative.

Allow for Risks and Aftercare

Do not assume that complications are included in the package price, or that a larger cell count has a predictable effect on risk. Ask who manages an adverse event, where urgent care is available and who pays for additional treatment. The FDA has reported serious harms from unapproved regenerative products, including infections, unwanted immune reactions and tumor formation; using cells from your own body does not remove all such concerns Important patient and consumer information about regenerative medicine therapies.

Approved products also have product-specific risks. For Ryoncil, the FDA lists common reactions including infection and fever, and warns of hypersensitivity, infusion reactions, transmitted infection and ectopic tissue formation. Shortness of breath, low blood pressure or blue discoloration during infusion require immediate attention from the treating team Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. These warnings do not establish that every cell therapy has the same risks or that doubling the dose doubles them.

Bottom line: Dose affects the bill through the provider’s pricing rules and the work included—not through a universal yen-per-cell rate. Compare the full course: 100 million cells once and 100 million cells twice are different plans. Confirm the total price, the evidence supporting the proposed dose and responsibility for aftercare before paying. No cell count guarantees a treatment benefit.

Not sure what your quote covers?

Send your planned dose, session count and yen total, and ask for the line-item breakdown before you pay.

Ask About Your Quote

References

  1. Remberger et al. The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors. Norway; retrospective cohort of 189 patients transplanted in 2005–2018. Transplant evidence, not a private-clinic dose or price standard. Accessed 30 October 2026.
  2. U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. 18 December 2024; United States; defined pediatric indication, study regimen, day-28 responses and safety information. Not a pricing source. Accessed 30 October 2026.
  3. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Historical U.S. consumer warning; used here for unapproved-product risks and the distinction between registration and legal marketing. Accessed 30 October 2026.
  4. Japanese Law Translation. Act on the Safety of Regenerative Medicine, particularly Articles 2–4. Japan; provision-plan and committee-review framework. Accessed 30 October 2026.
  5. Pharmaceuticals and Medical Devices Agency. Regenerative Medical Products. Japan; regulatory frameworks and approved-product information. Accessed 30 October 2026.